GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (NYSE:ZBH) » Definitions » Beneish M-Score

Zimmer Biomet Holdings (Zimmer Biomet Holdings) Beneish M-Score

: -2.52 (As of Today)
View and export this data going back to 2001. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.52 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Zimmer Biomet Holdings's Beneish M-Score or its related term are showing as below:

ZBH' s Beneish M-Score Range Over the Past 10 Years
Min: -2.83   Med: -2.48   Max: -2.07
Current: -2.52

During the past 13 years, the highest Beneish M-Score of Zimmer Biomet Holdings was -2.07. The lowest was -2.83. And the median was -2.48.


Zimmer Biomet Holdings Beneish M-Score Historical Data

The historical data trend for Zimmer Biomet Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.45 -2.48 -2.72 -2.47 -2.52

Zimmer Biomet Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.47 -2.45 -2.49 -2.49 -2.52

Competitive Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zimmer Biomet Holdings Beneish M-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Beneish M-Score falls into.



Zimmer Biomet Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zimmer Biomet Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9799+0.528 * 0.9872+0.404 * 0.984+0.892 * 1.0655+0.115 * 1.0476
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9648+4.679 * -0.01743-0.327 * 1.0039
=-2.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $1,442 Mil.
Revenue was 1940.1 + 1753.6 + 1869.6 + 1831 = $7,394 Mil.
Gross Profit was 1401.3 + 1235 + 1344.1 + 1330.2 = $5,311 Mil.
Total Current Assets was $4,610 Mil.
Total Assets was $21,497 Mil.
Property, Plant and Equipment(Net PPE) was $2,060 Mil.
Depreciation, Depletion and Amortization(DDA) was $952 Mil.
Selling, General, & Admin. Expense(SGA) was $2,839 Mil.
Total Current Liabilities was $2,857 Mil.
Long-Term Debt & Capital Lease Obligation was $5,013 Mil.
Net Income was 419.2 + 162.7 + 209.6 + 232.5 = $1,024 Mil.
Non Operating Income was -86.2 + -27.8 + -33.5 + -35.4 = $-183 Mil.
Cash Flow from Operations was 588.4 + 337.6 + 347.9 + 307.7 = $1,582 Mil.
Total Receivables was $1,382 Mil.
Revenue was 1825.1 + 1669.8 + 1781.8 + 1663.2 = $6,940 Mil.
Gross Profit was 1304.8 + 1181.6 + 1270.8 + 1163.2 = $4,920 Mil.
Total Current Assets was $4,427 Mil.
Total Assets was $21,066 Mil.
Property, Plant and Equipment(Net PPE) was $1,873 Mil.
Depreciation, Depletion and Amortization(DDA) was $926 Mil.
Selling, General, & Admin. Expense(SGA) was $2,762 Mil.
Total Current Liabilities was $2,358 Mil.
Long-Term Debt & Capital Lease Obligation was $5,324 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1442.4 / 7394.3) / (1381.5 / 6939.9)
=0.195069 / 0.199066
=0.9799

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4920.4 / 6939.9) / (5310.6 / 7394.3)
=0.709002 / 0.718202
=0.9872

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4609.5 + 2060.4) / 21496.9) / (1 - (4427.3 + 1872.5) / 21066)
=0.689727 / 0.700949
=0.984

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=7394.3 / 6939.9
=1.0655

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(926.4 / (926.4 + 1872.5)) / (951.7 / (951.7 + 2060.4))
=0.330987 / 0.315959
=1.0476

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2838.9 / 7394.3) / (2761.7 / 6939.9)
=0.383931 / 0.397945
=0.9648

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5012.6 + 2857.4) / 21496.9) / ((5324.2 + 2358.2) / 21066)
=0.366099 / 0.364682
=1.0039

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1024 - -182.9 - 1581.6) / 21496.9
=-0.01743

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zimmer Biomet Holdings has a M-score of -2.52 suggests that the company is unlikely to be a manipulator.


Zimmer Biomet Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zimmer Biomet Holdings (Zimmer Biomet Holdings) Business Description

Traded in Other Exchanges
Address
345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Executives
Syed A. Jafry director 345 E. MAIN STREET, WARSAW IN 46580
Sreelakshmi Kolli director C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Christopher B Begley director
Robert Hagemann director 3 GIRALDA FARMS, MADISON NJ 07940
Michael W Michelson director 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Betsy J Bernard director 711 HIGH STREET, DES MOINES IA 50392-0300
Arthur J Higgins director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Chad F Phipps officer: Assoc. Gen. Counsel, Corp. Sec C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Zuilen Wilfred Van officer: Pres, Europe, M. East & Africa 345 E. MAIN STREET, WARSAW IN 46580
Paul A Stellato officer: VP, Controller & CAO C/O XYLEM INC, 1 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Sang Yi officer: President, Asia Pacific 345 E. MAIN STREET, WARSAW IN 46580
Lori Winkler officer: SVP and CHRO 345 E. MAIN STREET, WARSAW IN 46580
Rachel Ellingson officer: SVP & CSO 345 E MAIN STREET, WARSAW K7 46580
Bryan C Hanson director, officer: President and CEO ZIMMER BIOMET HOLDINGS, 345 E. MAIN STREET, WARSAW IN 46580
Aure Bruneau officer: Group President 345 E. MAIN STREET, WARSAW IN 46580